If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> May 2012 660 Volume 11 • Issue 5<br /> Copyright © 2012<br /> CASE REPORT<br /> Journal of Drugs in Dermatology<br /> Treatment of Mild to Moderate Facial Melasma<br /> With the Lumixyl Topical Brightening System<br /> Basil M. Hantash MD PhDa and Felipe Jimenez PhDb<br /> aElixir Institute of Regenerative Medicine, San Jose, CA<br /> bEnvyMedical,Inc.,WestlakeVillage,CA<br /> ABSTRACT<br /> JDD<br /> Background: Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A propri-<br /> etary oligopeptide (LumixylTM) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the<br /> associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma.<br /> Objective: The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oli<a title="11-5_C735-Hantash-1 page 1" href="http://viewer.zmags.com/publication/fd0ff2b9?page=1"> May 2012 </a> <a title="11-5_C735-Hantash-1 page 2" href="http://viewer.zmags.com/publication/fd0ff2b9?page=2"> 661 Journal of Drugs in DerMatology May 2012 • </a> <a title="11-5_C735-Hantash-1 page 3" href="http://viewer.zmags.com/publication/fd0ff2b9?page=3"> 662 Journal of Drugs in DerMatology May 2012 • </a>